BioMarin Pharmaceutical's (BMRN) CEO J.J. Bienaime on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/26/21
BioMarin Appoints Former Goldman Sachs Partner and Life Sciences Executive, Maykin Ho, Ph.D. to Board of DirectorsPRNewsWire • 02/18/21
BioMarin's stock tumbles 6% after sharing data about experimental hemophilia A drugMarket Watch • 01/11/21
BioMarin Announces Positive Phase 3 Gene Therapy Trial Results in Adults with Severe Hemophilia A; Study Met All Primary and Secondary Efficacy Endpoints in One-Year Data SetPRNewsWire • 01/10/21
With Alexion Off the Board, Amarin and Biomarin Are Attractive Acquisition TargetsGuruFocus • 12/24/20
Goldman Sachs Adds Pharmaceutical Giant to Conviction List of Top Stocks to Buy24/7 Wall Street • 12/16/20
FINAL DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Reminds BioMarin Pharmaceutical Inc. Investors of Important November 24 Deadline in Securities Class Action - BMRNNewsfile Corp • 11/24/20
DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses of $100,000 to Contact the FirmBusiness Wire • 11/24/20
BIOMARIN 24 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - BMRNPRNewsWire • 11/24/20